Published studies of antiplatelet agents in patients with sickle cell disease (SCD).
| Study . | Genotype . | No. of patients . | Therapy . | Randomized . | Duration . | Efficacy outcome measure and results . |
|---|---|---|---|---|---|---|
| *Increase from baseline in hemoglobin (7.5 ± 0.35 g/dL to 10 ± 0.39 g/dL; P <.01), O2 saturation (80% ± 3.6% to 94% ± 3.7%, < .01), pO2 (52 ± 2.7 mm Hg to 68 ± 2.9 mmHg; P < .01), and decrease in 2,3-diphosphoglycerate levels (7.2 ± 0.24 μ mol/mL to < .01), 4.6 ± 0.20 μ mol/mL, P < .01) in patients on aspirin after 6 weeks of treatment. No data provided for patients in the control group. | ||||||
| †Decrease in number of crises (−81% vs −47%; P = .0001) and duration of crises (2.862 ± 1.75 days vs 3.952 ± 2.2 days; P = .001) in patients on ticlopidine vs placebo | ||||||
| Chaplin et al47 (1980) | HbSS | 3 | Aspirin/Dipyridamole | No | 104 weeks | Modest decrease in frequency of pain episodes, platelet count, and fibrinogen level |
| Osamo et al48* (1981) | HbSS | 100 | Aspirin | Yes | 6 weeks | Increase in oxygen affinity, hemoglobin, and RBC life span |
| Greenberg et al46 | HbSS | 40 | Aspirin vs placebo | Yes | 21 months | No decrease in frequency of pain |
| (1983) | HbSC | 8 | episodes | |||
| HbS-O Arab | 1 | |||||
| Semple et al36 (1984) | HbSS | 8 | Ticlopidine vs placebo | Yes | 4 weeks | No improvement in frequency of pain episodes or platelet survival, but decrease in platelet release products |
| HbS-β thalassemia | 1 | |||||
| Cabannes et al50† (1984) | HbSS | 140 | Ticlopidine vs placebo | Yes | 6 months | Reduction of frequency and duration of pain episodes |
| Zago et al49 (1984) | HbSS | 25 | Aspirin vs placebo | Yes | 5 months | No differences in frequency of pain episodes, hemoglobin, reticulocyte count, irreversibly sickled cells, and fetal hemoglobin level |
| HbS-β thalassemia | 4 | |||||
| Study . | Genotype . | No. of patients . | Therapy . | Randomized . | Duration . | Efficacy outcome measure and results . |
|---|---|---|---|---|---|---|
| *Increase from baseline in hemoglobin (7.5 ± 0.35 g/dL to 10 ± 0.39 g/dL; P <.01), O2 saturation (80% ± 3.6% to 94% ± 3.7%, < .01), pO2 (52 ± 2.7 mm Hg to 68 ± 2.9 mmHg; P < .01), and decrease in 2,3-diphosphoglycerate levels (7.2 ± 0.24 μ mol/mL to < .01), 4.6 ± 0.20 μ mol/mL, P < .01) in patients on aspirin after 6 weeks of treatment. No data provided for patients in the control group. | ||||||
| †Decrease in number of crises (−81% vs −47%; P = .0001) and duration of crises (2.862 ± 1.75 days vs 3.952 ± 2.2 days; P = .001) in patients on ticlopidine vs placebo | ||||||
| Chaplin et al47 (1980) | HbSS | 3 | Aspirin/Dipyridamole | No | 104 weeks | Modest decrease in frequency of pain episodes, platelet count, and fibrinogen level |
| Osamo et al48* (1981) | HbSS | 100 | Aspirin | Yes | 6 weeks | Increase in oxygen affinity, hemoglobin, and RBC life span |
| Greenberg et al46 | HbSS | 40 | Aspirin vs placebo | Yes | 21 months | No decrease in frequency of pain |
| (1983) | HbSC | 8 | episodes | |||
| HbS-O Arab | 1 | |||||
| Semple et al36 (1984) | HbSS | 8 | Ticlopidine vs placebo | Yes | 4 weeks | No improvement in frequency of pain episodes or platelet survival, but decrease in platelet release products |
| HbS-β thalassemia | 1 | |||||
| Cabannes et al50† (1984) | HbSS | 140 | Ticlopidine vs placebo | Yes | 6 months | Reduction of frequency and duration of pain episodes |
| Zago et al49 (1984) | HbSS | 25 | Aspirin vs placebo | Yes | 5 months | No differences in frequency of pain episodes, hemoglobin, reticulocyte count, irreversibly sickled cells, and fetal hemoglobin level |
| HbS-β thalassemia | 4 | |||||